Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
1(33.3%)
Phase 3
1(33.3%)
Phase 2
1(33.3%)
3Total
N/A(1)
Phase 3(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT03228498Phase 2Completed

Choline Alphoscerate-Nimodipine in Vascular Cognitive Impairment

Role: collaborator

NCT02912325Not ApplicableCompleted

Non-Comparative Study to Assess the Efficacy and Safety of the New Food Supplement FaseMETS

Role: lead

NCT02934061Phase 3Completed

Study to Assess the Efficacy and Safety of Tizaspray® Versus Sirdalud®, in Patients With Acute Low Back Pain

Role: lead

All 3 trials loaded